RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Background: Severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) infections and the resulting disease, coronavirus disease 2019 (COVID−19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Methods: Healthy a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:medRxiv
Glavni autori: Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Mulligan, Mark J, Bailey, Ruth, Swanson, Kena A, Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Thompkins, Kristin R, Lyke, Kirsten E., Raabe, Vanessa, Dormitzer, Philip R, Jansen, Kathrin U, Sahin, Uğur, Gruber, William C.
Format: Artigo
Jezik:Inglês
Izdano: Cold Spring Harbor Laboratory 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444302/
https://ncbi.nlm.nih.gov/pubmed/32839784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.08.17.20176651
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items